Vocabria

cabotegravir sodium · CABOTEGRAVIR SODIUM 30 mg/1 · Tablet, Film Coated · Oral · ViiV Healthcare Company

NDC 49702-0248-13 · 30 TABLET, FILM COATED in 1 BOTTLE · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$0.00

Reported to Texas DSHS · 2026 annual filing · ViiV Healthcare Company

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Regulatory

Application: NDA212887
TE code: —
Approval date: Jan 21, 2021
Patents / exclusivity: 2 patents, 1 exclusivities

Type	Number / code	Expires
exclusivity	NCE	Jan 21, 2026
patent	8410103	Feb 4, 2031
patent	10927129	Apr 28, 2026

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of cabotegravir sodium (Tablet, Film Coated)

Labeler	Strength	First seen	Last seen
Glaxo Operations UK Ltd	CABOTEGRAVIR SODIUM 30 mg/1	Jul 15, 2026	Sep 2, 2026
ViiV Healthcare Company	CABOTEGRAVIR SODIUM 30 mg/1	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Vocabria — NDC 49702-0248-13," retrieved September 3, 2026, https://drugdashboards.com/drug/49702024813.

Free to cite with attribution — see how the data is put together.